BRD4 and triple-negative breast carcinoma: Furthermore, MS645 is a bivalent BRD4 inhibitor that suppresses the proliferation of triple-negative breast cancer cells by blocking the binding of BRD4 to MED1 and YY1 transcription factors [101].